Table 2 Characteristics of antiretroviral treatment and virologic parameters of vertically HIV-1-infected children during follow-up.
Responders | Non-Responders | |
|---|---|---|
HAART during follow-up | ||
NNRTI or PI in first-line of HAART (b) | ||
Ritonavir | 4 (12.1%) | 32 (25.1%) |
Saquinavir | 6 (18.2%) | 12 (9.4%) |
Indinavir | 8 (24.2%) | 28 (22.1%) |
Nelfinavir | 10 (30.3%) | 44 (34.6%) |
Amprenavir | 3 (9.1%) | 5 (3.9%) |
Nevirapina | 0 (0%) | 6 (4.7%) |
Efavirenz | 6 (18.1%) | 10 (7.8%) |
ART-protocols switches (a) | 1 (0; 4) | 1 (0; 11) * |
Drugs switches (a) | 1 (0;7) | 3 (0;12) * |
Adherence >95% (b) | 30 (90.9%) | 61 (48%) * |
VL tests | ||
Total VL tests (a) | 20 (6; 34) | 21 (3; 48) |
Number of tests with VL ≤400 copies/mL (a) | 15 (5; 28) | 3 (0; 23) * |
Time to first uVL measure (a) | 3.7 (0.2; 12) | 29.4 (0.9; 59.8) * |
Time to last uVL measure (a) | 49.8 (16.1; 59.6) | 57.5 (31.8; 60) * |